Large-scale CRISPRi chemical genetic screening in Mycobacterium tuberculosis identifies genes altering antibiotic potency and the repurposing of the antibiotic clarithromycin to treat tuberculosis in Southeast Asia.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Li, S. et al. Nat. Microbiol. https://doi.org/10.1038/s41564-022-01130-y (2022).
Schnappinger, D. Cold Spring Harb. Perspect. Med. 5, a021139 (2015).
Schnappinger, D. & Ehrt, S. Microbiol. Spectr. 2, MGM2-0018-2013 (2014).
Bosch, B. et al. Cell 184, 4579–4592.e24 (2021).
Choudhary, E. et al. Nat. Commun. 6, 6267 (2015).
Singh, A. K. et al. Nucleic Acids Res. 44, e143 (2016).
Larrouy-Maumus, G. et al. ACS Infect Dis. 2, 352–360 (2016).
Gorla, P. et al. Front. Microbiol. 9, 2839 (2018).
Arenz, S. & Wilson, D. N. Cold Spring Harb. Perspect. Med. 6, a025361 (2016).
Burian, J. et al. Expert Rev. Anti. Infect. Ther. 10, 1037–1047 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
de Carvalho, L.P.S. Gene–drug potency screening in M. tuberculosis. Nat Microbiol 7, 743–744 (2022). https://doi.org/10.1038/s41564-022-01139-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41564-022-01139-3
